274,861 Shares in Immunome, Inc. $IMNM Purchased by Monashee Investment Management LLC

Monashee Investment Management LLC bought a new position in shares of Immunome, Inc. (NASDAQ:IMNM) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 274,861 shares of the company’s stock, valued at approximately $5,904,000. Immunome makes up 3.3% of Monashee Investment Management LLC’s holdings, making the stock its 12th biggest position. Monashee Investment Management LLC owned about 0.25% of Immunome as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Strs Ohio purchased a new position in Immunome during the fourth quarter worth about $64,000. Assetmark Inc. purchased a new position in Immunome during the third quarter worth about $39,000. BIT Capital GmbH purchased a new position in Immunome during the third quarter worth about $69,000. BNP Paribas Financial Markets grew its position in Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after buying an additional 2,909 shares in the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in Immunome during the third quarter worth about $76,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CFO Max Rosett sold 65,000 shares of the business’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $21.92, for a total value of $1,424,800.00. Following the completion of the sale, the chief financial officer owned 54,037 shares of the company’s stock, valued at approximately $1,184,491.04. The trade was a 54.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jean Jacques Bienaime bought 10,500 shares of the stock in a transaction dated Friday, June 5th. The stock was bought at an average cost of $19.45 per share, with a total value of $204,225.00. Following the purchase, the director owned 43,415 shares in the company, valued at $844,421.75. The trade was a 31.90% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders sold 139,438 shares of company stock worth $2,964,664. Insiders own 7.21% of the company’s stock.

Immunome Trading Up 1.1%

IMNM opened at $18.36 on Friday. The stock has a 50-day moving average price of $21.85 and a 200-day moving average price of $21.71. Immunome, Inc. has a 12-month low of $7.96 and a 12-month high of $27.65. The stock has a market capitalization of $2.08 billion, a P/E ratio of -7.71 and a beta of 2.04.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. On average, equities research analysts predict that Immunome, Inc. will post -2.06 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on IMNM shares. Leerink Partners reduced their target price on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Immunome in a report on Wednesday, May 13th. Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Truist Financial upped their price objective on Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Finally, Stephens cut their price objective on Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, March 4th. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $33.17.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.